Back to search

Article

Chronic Kidney Disease: A Benefit-Risk Panorama of Baricitinib through Integrating Network Toxicology, Molecular Docking and Real-World Evidence

2025-09-10

Abstract excerpt

<title>Abstract</title> <p>Background Chronic kidney disease (CKD) poses substantial global morbidity and mortality burdens, yet current therapeutic strategies fail to halt or reverse renal fibrosis. Baricitinib, a selective JAK1/JAK2 inhibitor, demonstrates dual anti-inflammatory and anti-fibrotic properties in autoimmune conditions; however, its comprehensive therapeutic utility and safety constraints in CKD re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d4429360-7dd8-528f-94a7-4bfe72fe0c47
DOI
10.21203/rs.3.rs-7498649/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Chronic Kidney Disease: A Benefit-Risk Panorama of Baricitinib through Integrating Network Toxicology, Molecular Docking and Real-World EvidenceDOI 10.21203/rs.3.rs-7498649/v1
Select a neighboring publication to make it the new centre.